Search research articles
Contact Us
Filters
Showing results (1-10 of 56) with videos related to
Page
of 6
Sort By:
Nature
|
November 21, 1998
Time to take a healthier view of history
I C Haznedaroglu
Experimental Hematology
|
January 29, 1999
A local renin--angiotensin system in the bone marrow: hypothesis and clues
I C Haznedaroglu
European Review for Medical and Pharmacological Sciences
|
January 4, 2022
Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
R Ciftciler, I C Haznedaroglu
Nigerian Journal of Clinical Practice
|
January 21, 2021
Clinical variations between three different causes of thrombocytopenia
S Akin, I C Haznedaroglu
European Review for Medical and Pharmacological Sciences
|
October 25, 2016
Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies
I C Haznedaroglu, U Y Malkan
European Review for Medical and Pharmacological Sciences
|
July 4, 2023
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
U Y Malkan, I C Haznedaroglu
European Review for Medical and Pharmacological Sciences
|
July 1, 2022
Hematological aspects of the COVID-19 syndrome
U Y Malkan, I C Haznedaroglu
Blood Purification
|
September 16, 1998
Hemostatic problems in uremia
I C Haznedaroglu, Y Büyükaşik, Y Erdem
Cancer
|
August 1, 1997
Extramedullary acute promyelocytic leukemia
M Benekli, M C Savaş, I C Haznedaroglu
The American Journal of Gastroenterology
|
February 1, 1997
Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis
A Kadayifci, I C Haznedaroglu, M C Savas
Page
of 6
Search research articles
Search
Showing results (1-10 of 56) with videos related to
Sort By:
Page
of 6
Nature
|
November 21, 1998
Time to take a healthier view of history
I C Haznedaroglu
Experimental Hematology
|
January 29, 1999
A local renin--angiotensin system in the bone marrow: hypothesis and clues
I C Haznedaroglu
European Review for Medical and Pharmacological Sciences
|
January 4, 2022
Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
R Ciftciler, I C Haznedaroglu
Nigerian Journal of Clinical Practice
|
January 21, 2021
Clinical variations between three different causes of thrombocytopenia
S Akin, I C Haznedaroglu
European Review for Medical and Pharmacological Sciences
|
October 25, 2016
Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies
I C Haznedaroglu, U Y Malkan
European Review for Medical and Pharmacological Sciences
|
July 4, 2023
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
U Y Malkan, I C Haznedaroglu
European Review for Medical and Pharmacological Sciences
|
July 1, 2022
Hematological aspects of the COVID-19 syndrome
U Y Malkan, I C Haznedaroglu
Blood Purification
|
September 16, 1998
Hemostatic problems in uremia
I C Haznedaroglu, Y Büyükaşik, Y Erdem
Cancer
|
August 1, 1997
Extramedullary acute promyelocytic leukemia
M Benekli, M C Savaş, I C Haznedaroglu
The American Journal of Gastroenterology
|
February 1, 1997
Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis
A Kadayifci, I C Haznedaroglu, M C Savas
Page
of 6